We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Be SMART NIS, Moderate to Servere Asthma Patient Observation

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00514787
First Posted: August 10, 2007
Last Update Posted: March 27, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
Screen for moderate to severe asthma patients with suboptimal asthma control (as defined by GINA-Guidelines). Document current asthma control status. Re-evaluate asthma therapy and document new therapy if applicable.

Condition
Asthma

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Be SMART NIS, Moderate to Servere Asthma Patient Observation

Further study details as provided by AstraZeneca:

Estimated Enrollment: 900
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Moderate to severe asthma with suboptimal control

Exclusion Criteria:

  • Intermittent or mild asthma, patient with good asthma control
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00514787


Locations
Austria
Research Site
Vienna, Austria
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Wolfgang Pohl, PHD Executive Board OGP (Austria Society of Pneumology
  More Information

ClinicalTrials.gov Identifier: NCT00514787     History of Changes
Other Study ID Numbers: NIS-RAT-SYM-2007/1
First Submitted: August 9, 2007
First Posted: August 10, 2007
Last Update Posted: March 27, 2009
Last Verified: March 2009

Keywords provided by AstraZeneca:
Asthma
NIS

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases